MedDataX Logo

Efficacy of Olmesartan on Cerebral Glucose Metabolism, Vascular Inflammation and Adipose Tissue

NCT ID: NCT02996916

Last Updated: 2016-12-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-12-31

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hypertension is a leading risk factor for morbidity and mortality worldwide. The brain is a major target of the damaging effects of hypertension. Hypertension has been recognized as the leading cause of dementia as well as the most important risk factor for stroke and vascular cognitive impairment. Although glucose is the principal cerebral energy source, impact of hypertensive treatment on cerebral glucose metabolism is poorly understood.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Efficacy of Olmesartan on Cerebral Glucose Metabolism in Essential Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Olmesartan

Olmesartan 10-40mg daily

Group Type ACTIVE_COMPARATOR

Olmesartan

Intervention Type DRUG

10-40mg daily

Amlodipine

Amlodipine 2.5-10mg daily

Group Type ACTIVE_COMPARATOR

Amlodipine

Intervention Type DRUG

2.5-10mg daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Olmesartan

10-40mg daily

Intervention Type DRUG

Amlodipine

2.5-10mg daily

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent obtained
* Male and female subjects aged 20 years or older at informed consent
* Essential hypertension who had never received angiotensin II receptor antagonists and calcium channel blockers

Exclusion Criteria

* Secondary hypertension or malignant hypertension
* Diabetes mellitus
* History or evidence of a stroke
* Hepatic or hematologic abnormality
* Mild Cognitive Impairment or Dementia
* Serum potassium level ≥ 5.5 mEq/L
* Serum creatinine level ≥ 3.0 mg/dL
* Acute or chronic disease
* Allergy to any drugs
* Pregnancy
Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kurume University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Nobuhiro Tahara

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nobuhiro Tahara, MD, PhD

Role: STUDY_CHAIR

Department of Medicine, Division of Cardiovascular Medicine, Kurume University School of Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kurume University Hospital

Kurume, , Japan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Japan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Nobuhiro Tahara, MD, PhD

Role: CONTACT

Phone: +81-942-31-7580

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Nobuhiro Tahara, MD, PhD

Role: primary

Akihiro Honda, MD, PhD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Olme-brain

Identifier Type: -

Identifier Source: org_study_id